Frontier Resources (AIM:FRI), agreed to acquire Concepta Diagnostics Limited (“Concepta”), a pioneering UK healthcare company established in 2013, that has developed proprietary products and a platform, which targets the personalised mobile health market with a primary focus on women’s fertility and specifically unexplained infertility. SPARK Advisory Partners is acting as Nominated Adviser and Financial Adviser to the Company with Beaufort Securities as Broker.

This acquisition has been completed, FRI is now CPT

From RNS 26.7.2016:- "Mercia Technologies PLC (AIM: MERC), which is focused on the creation, funding and scaling of innovative businesses with high growth potential from the UK regions, is delighted to announce the successful admission of the enlarged share capital of Concepta PLC ("Concepta", AIM: CPT), one of its direct portfolio companies formerly named Concepta Diagnostics Ltd, to trading on AIM at 8.00am today."


http://www.conceptaplc.com/concepta/about-us
Concepta's flagship product MyLotus has a unique offering, allowing women to see YES / NO results as well as their actual and personal level of factors that can have a direct influence on fertility – MyLotus is the only home-test on the market that currently offers this.

MyLotus has the ability to quantify personal hormone levels enabling the identification of the fertile period for a large number of women, especially for the significant amount of women whose hCG and LH levels vary from mean levels.

Concepta gives positive update on myLotus in China

StockMarketWire.com

Concepta has announced a positive update on the launch of its proprietary myLotus product in its first international market, China.

The company has signed an additional two three-year exclusive distribution agreements for myLotus with Huanzhong Biotech and Wanma Technology Co in China.

The distribution agreement with Huanzhong Biotech Ltd will cover the province of Hebei near Beijing, while Wanma Technology Co will cover the Shanghai area.

It said: 'Alongside ThinkBrio, which distributes the myLotus product to Beijing and Lianoing, these two agreements will expand Concepta's product offering in China to target a total population of 147 million people across these regions.'

Concepta also said it had completed a preliminary hospital evaluation process in China to extend the use of myLotus into early pregnancy monitoring.

It said:'Based on recent positive hospital evaluation results, the Company's new distributors, Huanzhong Biotech Ltd and Wanma Technology will be the first to target the "early pregnancy" group alongside the "unexplained infertility" target group.

'There is a total target market of 2.3 million women a year across the Hebei, Beijing, Lianoing and Shanghai areas for early pregnancy monitoring.'

Chief executive Erik Henau said: 'We are delighted to add these new distributors to our network in China, following the Company's excellent preliminary hospital evaluation results.

'Following the final conclusion of the evaluation, an event will be held in China for a large number of potential distributors where we will exhibit the myLotus product.

'We expect to announce further distribution agreement signings following this event.'

At 9:46am: (LON:CPT) Concepta Plc Ord 2.5p share price was +0.75p at 10p


Story provided by StockMarketWire.com